Linezolid induced pancytopenia in a patient of extensively drug-resistant pulmonary tuberculosis: An unusual outcome
Linezolid (Lnz) is the first oxazolidinones to be developed and introduced in clinical use. Its use is growing by day and day in the treatment of resistant pulmonary tuberculosis (TB). Lnz has been associated with adverse hematological effects, primarily thrombocytopenia. But pancytopenia is a very...
Main Authors: | Rajiv Garg, Ashwini Kumar Mishra, RamAwadh Singh Kushwaha, Anubhuti Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | The Journal of Association of Chest Physicians |
Subjects: | |
Online Access: | http://www.jacpjournal.org/article.asp?issn=2320-8775;year=2016;volume=4;issue=1;spage=21;epage=23;aulast=Garg |
Similar Items
-
Complications of MRSA Treatment: Linezolid-induced Myelosuppression Presenting with Pancytopenia
by: Gorchynski, Julie A, et al.
Published: (2008-08-01) -
A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency
by: Yingying Wang, et al.
Published: (2021-05-01) -
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
by: Marie Jaspard, et al.
Published: (2017-10-01) -
Safety of longer linezolid regimen in children with drug-resistant tuberculosis and extensive tuberculosis in Southwest China
by: ZhenZhen Zhang, et al.
Published: (2020-06-01) -
Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)